Enhanced Bioavailability of a Novel Oil-Based Lutein Formulation: A Randomized, Double-Blind, Single-Dose, Comparative Oral Bioavailability Study in Healthy Adults

Lutein is a xanthophyll carotenoid valued for ocular health, but its systemic bioavailability varies widely depending on formulation. This publication reports a randomized, double-blind, single-dose, parallel-group study in 80 healthy adults comparing a novel oil-suspension lutein formulation against a commercially available reference formulation under fed conditions. Pharmacokinetic parameters, including Cmax and multiple AUC measures, were derived by non-compartmental analysis using Phoenix WinNonlin. The novel formulation produced significantly higher serum lutein concentrations than the reference product from 8 through 72 hours post-dose, with total systemic bioavailability increased by roughly 35-39% and Cmax approximately 32% higher. Both formulations were well tolerated, and the authors conclude that formulation design plays a critical role in lutein bioavailability, warranting further clinical efficacy studies.